BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual Meeting
read more...
Dec 09, 2017
BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma at the 59th American Society of Hematology Annual Meeting
read more...
Dec 09, 2017
BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual Meeting
read more...
Dec 04, 2017
BeiGene to Webcast an Analyst and Investor Event from the American Society of Hematology Annual Meeting
read more...
Nov 13, 2017
BeiGene Expands Global Pivotal Program for BTK Inhibitor BGB-3111
read more...
Nov 13, 2017
BeiGene Reports Third Quarter 2017 Financial Results
read more...
Nov 01, 2017
BeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual Meeting
read more...
Sep 28, 2017
BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO
read more...
Sep 21, 2017
BeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical Oncology
read more...
Sep 11, 2017
BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 Congress
read more...
Sep 08, 2017
BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress
read more...
Aug 31, 2017
BeiGene Announces Closing of Global Strategic Oncology Collaboration with Celgene Corporation
read more...
Aug 30, 2017
BeiGene Announces Presentations at the European Society for Medical Oncology 2017 Congress
read more...
Aug 30, 2017
BeiGene to Present at Upcoming Investor Conferences
read more...
Aug 10, 2017
BeiGene Announces Pricing of $175 Million Public Offering
read more...
Aug 09, 2017
BeiGene Announces Proposed Public Offering
read more...
Aug 09, 2017
BeiGene Reports Second Quarter 2017 Financial Results
read more...
Jul 05, 2017
BeiGene to Host Investor Conference Call on Global Strategic Collaboration with Celgene
read more...
Jul 05, 2017
BeiGene Initiates Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer
read more...
Jun 29, 2017
BeiGene Presents Preliminary Phase 1 Data on BGB-A317 in Patients with Hepatocellular Carcinoma at the ESMO 19th World Congress on Gastrointestinal Cancer
read more...
